Collegium Affirms FY2026 Sales Guidance of $825M-$855M
Collegium Pharmaceutical affirmed FY2026 sales guidance of $825.000M-$855.000M, versus an estimate of $835.780M.
Related stories
Gibraltar Industries Sees 2026 Adjusted EPS of $2.25-$2.40 Excluding Infrastructure
M impact | EARNINGS | Nov 05, 2026, 12:48 PM UTC
Payoneer Posts Q3 EPS of $0.04, Below $0.05 Estimate
M impact | EARNINGS | Nov 05, 2026, 12:47 PM UTC
BCE Third-Quarter Profit Falls as Revenue Rises 2.2%
BCE said lower net income reflected a comparison with last year's sale of its Toronto Maple Leafs and Raptors stake. Revenue rose 2.2% on stronger broadband and media sales.
M impact | EARNINGS | Nov 05, 2026, 12:47 PM UTC
Southern Co.'s Q3 Adjusted EPS Beats Estimates on Warmer Weather
M impact | EARNINGS | Nov 05, 2026, 12:47 PM UTC
National Grid earnings above expectations at 0.36 GBP
National Grid (NG) released earnings per share at 0.36 GBP, compared to market expectations of 0.00 GBP.
H impact | EARNINGS | Nov 05, 2026, 12:47 PM UTC
Advanced Flower Capital Reports Third-Quarter NII of $3.5 Million
Advanced Flower Capital reported third-quarter 2026 net investment income of $3.5 million, or $0.16 per weighted average share, on total investment income of $8.6 million. Net asse
M impact | EARNINGS | Nov 05, 2026, 12:46 PM UTC